| pembrolizumab based treatment |
| pembrolizumab alone | pembrolizumab and pemetrexed plus platin | pembrolizumab plus SoC |
mNSCLC - L1 - all population 5 | | | |
mNSCLC - L1 - EGFR mutant | | | |
mNSCLC - L1 - PDL1 negative 1 | | | |
mNSCLC - L1 - PDL1 positive 14 | | | |
mNSCLC - L1 - TMB>10Mb 1 | | | |
non squamous cell - mNSCLC - L1 | | | |
non squamous - mNSCLC - L1 - all population 3 | | | |
non squamous - mNSCLC - L1 - PDL1 positive | | | |
non squamous - mNSCLC - L1 - Wild Type (WT) 6 | | | |
squamous cell - mNSCLC - L1 | | | |
squamous - mNSCLC - L1 - all population 4 | | | |
squamous - mNSCLC - L1 - PDL1 positive | | | |
squamous - mNSCLC - L1 - Wild Type (WT) | | | |